Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Neutral → Sell | BTIG Research | |
| 5/10/2024 | Mkt Perform → Underperform | William Blair | |
| 11/14/2023 | $3.50 → $2.50 | Outperform → Mkt Perform | Raymond James |
| 11/9/2023 | Buy → Neutral | BTIG Research | |
| 6/2/2023 | $3.00 → $1.25 | Neutral → Sell | Goldman |
| 5/11/2023 | Outperform → Mkt Perform | William Blair | |
| 11/29/2022 | $6.00 | Buy | Berenberg |
| 10/4/2022 | $5.00 | Equal-Weight | Morgan Stanley |
BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", or the ", Company", )), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting
New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15
Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo